Personalized prediction of initial valproic acid dose in children with epilepsy using machine learning techniques

Read full text Summarise with VIRAT
Authors: Yu Zhang, Shuoqi Ren, Jing Yu, Shiqi Xu, Yujuan Zhang, Jinyuan Zhang, Xiaodong Li, Jianfang Shao, Lijuan Lu, Fei Gao, Jian Tian
Cited by: 0
References: 43

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Valproic acid (VPA) is widely prescribed antiepileptic drug in children because of its broad-spectrum efficacy. However, marked inter-individual variability in pharmacokinetics makes dose optimization challenging. Inappropriate initial dosing can lead to subtherapeutic exposure or toxicity, including hepatotoxicity, encephalopathy, and hematological adverse effects. Despite the importance of early dose selection, reliable methods for predicting individualized initial daily doses of VPA in pediatric epilepsy are lacking. AIM: This study aimed to develop and internally validate a predictive model for the initial daily dose of VPA in pediatric epilepsy patients based on a real-world clinical database using artificial intelligence techniques. METHOD: A retrospective cohort of pediatric epilepsy patients treated with VPA was recruited from Baoding Children's Hospital between December 2017 and November 2023. Eligible patients were aged 1-16 years, received oral VPA therapy, and underwent therapeutic drug monitoring. Data pre-processing included z-score standardization, one-hot encoding, and Random Forest imputation for missing values. Variable selection was performed by univariate analysis and sequential forward selection. The dataset (306 VPA dose samples from 184 patients) was randomly divided into training (80%) and testing (20%) sets. Ten machine learning and deep learning algorithms-CatBoost, XGBoost, LightGBM, Random Forest, Support Vector Machine, Multilayer Perceptron, Artificial Neural Network, Transformer, AdaBoost, and TabNet-were trained with tenfold cross-validation. The model performance was assessed using the coefficient of determination (R2), root mean square error (RMSE), mean absolute error (MAE), and mean absolute percentage error (MAPE). RESULTS: = 0.730, RMSE = 0.153, MAE = 0.116, and MAPE = 18.19% in the test set. The proportions of predictions within ± 30, ± 40, and ± 50% of the actual dose were 85.48, 91.94, and 95.16%, respectively. CONCLUSION: The TabNet-based model demonstrated strong predictive ability for estimating individualized initial VPA doses in pediatric epilepsy in a single-center cohort with internal validation only. By integrating readily available demographic and laboratory parameters, the model and its accompanying online tool have the potential to offer a practical decision-support resource for clinicians and pharmacists to improve dosing precision, enhance safety, and optimize therapeutic outcomes; however, the generalizability of this internally validated model to other hospitals, populations, and ethnic groups is unknown, and external validation is required before clinical implementation.

Fields of Study & Subjects

Epilepsy research and treatment Pharmaceutical studies and practices Machine Learning in Healthcare

Publication details

Journal / source
International Journal of Clinical Pharmacy
Volume
48
Issue
3
Pages
992–1003
Publication date
25 March 2026
Language
EN